Portal de Periódicos da CAPES

Inotropic drugs of the future*

1982; Wiley; Volume: 12; Issue: 6 Linguagem: Inglês

10.1111/j.1365-2362.1982.tb02221.x

1365-2362

H. Pouleur, J M Detry, Giuseppe Mancia,

Computational Drug Discovery Methods

European Journal of Clinical InvestigationVolume 12, Issue 6 p. 441-443 Inotropic drugs of the future* H. POULEUR, Corresponding Author H. POULEUR University of Louvain, School of Medicine, Brussels, BelgiumDr H. Pouleur, Université de Louvain, Fac. de Médecine, Avenue Hippocrate, 55 Box 5560, B-1200 Brussels, Belgium.Search for more papers by this authorJ. M. DETRY, J. M. DETRY University of Louvain, School of Medicine, Brussels, BelgiumSearch for more papers by this authorG. MANCIA, G. MANCIA University of Milan, School of Medicine, Milan, Italy University of Louvain, School of Medicine, Brussels, BelgiumSearch for more papers by this author H. POULEUR, Corresponding Author H. POULEUR University of Louvain, School of Medicine, Brussels, BelgiumDr H. Pouleur, Université de Louvain, Fac. de Médecine, Avenue Hippocrate, 55 Box 5560, B-1200 Brussels, Belgium.Search for more papers by this authorJ. M. DETRY, J. M. DETRY University of Louvain, School of Medicine, Brussels, BelgiumSearch for more papers by this authorG. MANCIA, G. MANCIA University of Milan, School of Medicine, Milan, Italy University of Louvain, School of Medicine, Brussels, BelgiumSearch for more papers by this author First published: December 1982 https://doi.org/10.1111/j.1365-2362.1982.tb02221.xCitations: 5 * During the yearly meeting of the European Society of Clinical Investigation, Luxembourg, April 1982, a workshop was held with the title of the editorial (Organizers: J. M. Detry and H. Pouleur). AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Doherty JE, Kane JJ. Clinical pharmacology of digitalis glycosides. Ann Rev Med 1975; 26: 159–79. 2 Guz A. The clinical value of digoxin in patients with heart failure and sinus rhythm. In: CJ Dickinson, J Marks, eds. Developments in cardiovascular medicine. Lancaster : MTP Press, 1978: 255–61. 3 Goldberg LI. Use of sympathomimetic amines in heart failure. Am J Cardiol 1968; 22: 177–82. 4 Alousi AA, Farah AE, Lesher GY, Opalka CJ Jr. Cardiotonic activity of Amrinone-Win 40680 (5-Amino-3,4′-bipyridin-6 (1H)-one). Circ Res 1979; 45: 666–77. 5 Diederen W, Kadatz R. Effects of AR-L115 BS, a new cardiotonic compound, on cardiac contractility, heart rate and blood pressure in anesthetized and conscious animals. Drug Res 1981; 31: 146–50. 6 Ariens EJ. Molecular pharmacology. The mode of action of biologically active compounds. New York : Academic Press, 1964: 146–70. 7 Benotti JR, Grossman W, Braunwald E, Carabello BA. Effects of amrinone on myocardial energy metabolism and haemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 1980; 62: 28–34. 8 Jennings K, Gwilt D, Crean P, Gold RG, Julian DG. The clinical pharmacology of a new cardiotonic agent oral and intravenous amrinone. (Abstract). Eur J Clin Invest 1982; 12(II): 48. 9 Col J, Cheron P, Jouret G, Harvengt C, Pétein M. Haemodynamic effects of AR-L115 BS in severe chronic congestive heart failure. (Abstract). Eur J Clin Invest 1982; 12(II): 47. 10 Hagemeijer F, Schelling A, Van Mechelen R. Hemodynamic effects of sulmazol (AR-L115 BS) administered intravenously to patients with severe left ventricular failure. (Abstract). Eur J Clin Invest 1982; 12(II): 48. 11 Goenen M, Leenaerts L, Susini G, Trémouroux J. Haemodynamic effects of prenalterol, a new βt stimulating agent, early after open heart surgery. (Abstract). Eur J Clin Invest 1982; 12(II): 48. 12 Hansteen V, Minichen E, Lorentsen E, Andersen A, Strøm O, Søiland K, Dyrbekk D, Refsum AM, Tromsdal A, Knudsen K, Eika C, Bakken J, Smith P, Hoff PI. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J 1982; 284: 155–60. 13 Moss AJ, Davis HT, Conard DL, DeCamilla JJ, Odoroff CL. Digitalis-associated cardiac mortality after myocardial infarction. Circulation 1981; 64: 1150–6. 14 Mancia G, Gregorini L, Albini F, Buccino N, Ferrari A, Zanchetti A. Cardiovascular effects of ICI 118, 587 in subjects with reduced cardiac reserve. (Abstract). Eur J Clin Invest 1982; 12(II): 49. 15 De Coster PM, Brasseur LA, Rousseau MF, Wyns W, Detry JM. Hemodynamic effects of a new cardioselective beta-adrenoceptor antagonist with partial agonist activity (ICI 118, 587). (Abstract). Eur J Clin Invest 1982; 12(II): 48. 16 Hutton I, Clark RS, Martin W, McKillop JH, Tweddel AC. Oral prenalterol in chronic congestive cardiac failure. (Abstract). Eur J Clin Invest 1982; 12(II): 48. 17 Hamm CW, Kupper W, Schutt M, Bleifeld WH. The effects of beta-I-agonist prenalterol on haemodynamics and myocardial metabolism in patients with chronic heart failure. (Abstract). Eur J Clin Invest 1982; 12(II): 48. 18 Pouleur H, Rousseau MF, Mengeot P, Veriter C, Vincent MF, Brasseur LA. Improvement of global and regional left ventricular function in patients with previous myocardial infarction by a new β1 adrenoceptor partial agonist, ICI 118, 587. Eur Heart J 1982:in press. Citing Literature Volume12, Issue6December 1982Pages 441-443 ReferencesRelatedInformation